Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
Clinical Pearls
Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
The NeoALTTO trial set out to determine whether the higher pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival
The hazard for event-free survival was 65%-70% lower for patients who achieved pCR than for those who did not
This trial is important because the FDA now allows for the approval of novel therapies following testing in the adjuvant setting
